News

Addex Pharmaceuticals and Merck affiliate to collaborate

Addex Pharmaceuticals SA and Merck, Sharp and Dohme Research Ltd, an affiliate of Merck & Co, have entered into an exclusive collaboration and licensing agreement to develop a new class of ingested drugs that potentially will treat Parkinson’s disease and other diseases.

e-Therapeutics raises funds with IPO in London

e-Therapeutics, which uses informatics for discovering the safety and efficacy of new combinations or applications of existing medical compounds, has received a listing on the Alternative Investment Market (AIM) of the London Stock Exchange.

Photocure to ‘de-merge’ its subsidiary, PCI Biotech

Photocure ASA, a Norwegian company that has developed a photosensitive method of killing cancer cells, is ‘de-merging’ its 91.4%-owned subsidiary, PCI Biotech, by distributing shares in the subsidiary to its existing shareholders on a one-for-one basis.

Hybrigenics raising funds with an IPO in Paris

Hybrigenics SA, a French proteomics specialist with a drug candidate in Phase 2 development for treating prostate cancer, is raising between €24.2 million and €28.1 million in an initial public offering (IPO) of its shares on the Alternext section of the Euronext Paris stock exchange.

Olympus Corp of Japan to acquire Gyrus Group Plc

Olympus Corp of Japan has made an agreed cash offer of £935 million to buy all the shares of the Gyrus Group Plc, a British manufacturer of medical devices, including systems for laparoscopic and endoscopic procedures.